Stem cell transplant for chronic myeloid leukemia in the imatinib era.
Stem cell transplant for chronic myeloid leukemia in the imatinib era.
复制标题
DOI：
10.1053/j.seminhematol.2010.06.008
复制
发表时间：
2010-10
影响因子：
3.6
通讯作者：
Radich J
中科院分区：
文献类型：
--
作者：
Radich J
Tyrosine kinase inhibitor (TKI) therapy has revolutionized the therapy of CML. Thus, while in the near past allogeneic transplantation was the curative option for CML, imatinib, nilotinib, and dasatinib have pushed transplantation to the role of salvage therapy in CML. Still, TKI therapy still fails some patients, and so the clinical challenge is to integrate transplantation in a safe and sane manner. This manuscript reviews the data on the variables that influence outcome following transplantation, and discusses the variables to consider in determining which patients should receive transplantation and when.
登录
查看更多内容
影响因子：
158.5
作者：
Hansen, JA;Gooley, TA;Anasetti, C
通讯作者：
Anasetti, C
影响因子：
20.3
作者：
Carpenter, Paul A.;Snyder, David S.;Radich, Jerald P.
通讯作者：
Radich, Jerald P.
影响因子：
20.3
作者：
Cortes, Jorge;Rousselot, Philippe;Baccarani, Michele
通讯作者：
Baccarani, Michele
影响因子：
158.5
作者：
Kantarjian, Hagop;Giles, Francis;Ottmann, Oliver G.
通讯作者：
Ottmann, Oliver G.
影响因子：
158.5
作者：
FEFER, A;CHEEVER, MA;THOMAS, ED
通讯作者：
THOMAS, ED